---
title: "Cedaar Textile Ltd (CEDAAR) — Share Price, Financials & Analysis"
symbol: "CEDAAR"
company: "Cedaar Textile Ltd"
canonical: "https://tapetide.com/stocks/CEDAAR"
isin: "INE11J101017"
nse_symbol: "CEDAAR"
sector: "Textiles"
industry: "Textiles & Apparels"
market_cap_cr: 17.49
generated_at: "2026-09-13T21:38:43.994Z"
---

# Cedaar Textile Ltd (CEDAAR)

Canonical page: https://tapetide.com/stocks/CEDAAR

## Company

- **NSE Symbol:** CEDAAR
- **ISIN:** INE11J101017
- **Sector:** Textiles
- **Industry:** Textiles & Apparels
- **Macro Sector:** Consumer Discretionary
- **Stock Type:** EQUITY
- **Listed Since:** 2025-07-07
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** cedaartextile.com

## About

Incorporated in 2020, Cedaar Textile Ltd is in the business of manufacturing and exporting yarns[1]

## Latest Price

- **Price:** ₹12.6
- **Change:** +0.15 (+1.2%)
- **Open:** ₹12.6
- **Day High:** ₹12.95
- **Day Low:** ₹12.6
- **Previous Close:** ₹12.45
- **Volume:** 9000
- **As Of:** 2026-09-11T09:57:01+00:00

## Key Fundamentals

Observed at 2026-09-11T04:47:07.445669Z.

- **Market Cap:** ₹17.49 Cr
- **Classification:** SME
- **P/E (reported):** -0.2
- **Book Value:** ₹34.89
- **Price to Book:** 0.36
- **Dividend Yield:** 0%
- **ROE:** 18.33%
- **ROCE:** 26.72%
- **Debt to Equity:** 2.18
- **Revenue (yearly):** ₹162.8 Cr
- **Net Income:** ₹-95.51 Cr
- **EBITDA:** ₹-82.89 Cr
- **52-Week High:** ₹113
- **52-Week Low:** ₹12.45
- **RSI (14):** 26.99

## Tapetide Score

- **Score:** 35 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Falling
- **Percentile:** 6 (of 4473 scored stocks)
- **Confidence:** 81%
- **Data coverage:** 62%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 5.93 | 9% |
| growth | 20.03 | 9% |
| momentum | 2.75 | 12% |
| ownership | 67.95 | 24% |
| quality | 42.92 | 22% |
| valuation | 43.09 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.36 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of -38.3% over last 3 years.
- Debtor days have increased from 61.3 to 104 days.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 177.13% | 978.06% | 820.08% |
| ebitda margin growth | -432.28% | -417% | -706.51% |
| net income growth | -895.92% | -889.34% | — |
| revenue growth | -22.22% | 1% | -5.88% |
| roce | 0.83% | 82.64% | 21.76% |
| roe | -61.76% | 32.87% | -43.34% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 71 | 79 | 130 | 81 | 82 |
| Expenses | 60 | 65 | 113 | 74 | 172 |
| Operating Profit | 11 | 14 | 17 | 7 | -90 |
| OPM % | 16 | 18 | 13 | 9 | -110 |
| Other Income | 1 | 1 | 0 | 1 | 1 |
| Interest | 6 | 6 | 5 | 6 | 4 |
| Depreciation | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 4 | 7 | 9 | 0 | -96 |
| Tax % | 23 | 26 | 27 | -664 | -22 |
| Net Profit | 3 | 5 | 7 | 4 | -75 |
| EPS in Rs | 4.44 | 5.33 | 7.3 | 2.75 | -54.18 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 217 | 160 | 188 | 207 | 163 |
| Expenses | 201 | 141 | 158 | 175 | 246 |
| Operating Profit | 16 | 19 | 30 | 32 | -83 |
| OPM % | 7 | 12 | 16 | 15 | -51 |
| Other Income | 3 | 2 | 2 | 1 | 2 |
| Interest | 7 | 11 | 13 | 12 | 10 |
| Depreciation | 3 | 3 | 4 | 4 | 5 |
| Profit before tax | 9 | 6 | 15 | 16 | -96 |
| Tax % | 13 | 29 | 21 | 26 | -25 |
| Net Profit | 8 | 5 | 12 | 12 | -71 |
| EPS in Rs | 319.6 | 183.6 | 16.13 | 12.64 | -51.43 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.25 | 0.25 | 8 | 10 | 14 |
| Reserves | 9 | 14 | 18 | 56 | 35 |
| Borrowings | 121 | 137 | 146 | 116 | 107 |
| Other Liabilities | 24 | 25 | 27 | 45 | 72 |
| Total Liabilities | 154 | 176 | 198 | 226 | 228 |
| Fixed Assets | 70 | 74 | 78 | 77 | 75 |
| CWIP | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 84 | 101 | 121 | 149 | 153 |
| Total Assets | 154 | 176 | 198 | 226 | 228 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -15 | -2 | 6 | 17 | -32 |
| Cash from Investing Activity | -6 | -6 | -4 | -4 | 6 |
| Cash from Financing Activity | 22 | 8 | -2 | -13 | 36 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 11 |
| Free Cash Flow | -19 | -9 | -1 | 14 | -35 |
| CFO/OP | -92 | -5 | 25 | 55 | 31 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 45 | 55 | 46 | 34 | 104 |
| Inventory Days | 69 | 207 | 253 | 300 | 54 |
| Days Payable | 44 | 62 | 53 | 76 | 46 |
| Cash Conversion Cycle | 70 | 200 | 246 | 259 | 112 |
| Working Capital Days | -3 | 22 | 25 | 26 | -87 |
| ROCE % | — | 12 | 17 | 17 | -51 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2024 | Jun 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Promoters | 100% | 100% | 68.66% | 68.66% |
| FIIs | 0% | 0% | 0% | 0.07% |
| DIIs | 0% | 0% | 0% | 2.58% |
| Government | 0% | 0% | 0% | 0% |
| Public | 0% | 0% | 17.38% | 21.26% |
| Others | 0% | 0% | 13.96% | 7.43% |
| No. of Shareholders | 7 | 7 | 1465 | 1453 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 6 / 2 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 13.47 | Sell |
| EMA (10) | 13.37 | Sell |
| SMA (20) | 14 | Sell |
| EMA (20) | 14.16 | Sell |
| SMA (50) | 16.67 | Sell |
| EMA (50) | 16.77 | Sell |
| SMA (100) | 21.77 | Sell |
| EMA (100) | 22.8 | Sell |
| SMA (200) | 36.07 | Sell |
| EMA (200) | 42.51 | Sell |

### Oscillators — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 28.99 | Buy |
| MACD (12,26,9) | -1.12 | Buy |
| Stochastic (14,3,3) | 8.9 | Buy |
| ADX (14) | 41.1 | Buy |
| Williams %R (14) | -94.44 | Buy |
| ATR (14) | 0.79 | High Volatility |
| ROC (12) | -12.8 | Sell |
| Stoch RSI (14) | 18.78 | Buy |
| UO (7,14,28) | 46.11 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - CBI searched Vivimed on Jan 20; High Court granted interim stay on Feb 6, 2026 against coercive action. | [Disclosure Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015 (Listing Regulations) 9 Feb - CBI searched Vivimed on Jan 20; High Court granted interim stay on Feb 6, 2026 against coercive action.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f5b3826-0551-4bd3-a7eb-2a13a0282a02.pdf) |
| 8 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical share certificates received for dematerialization. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 8 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical share certificates received for dematerialization.](https://nsearchives.nseindia.com/corporate/CEDAAR_08042026191146_NSE_74_5__DP_Compliance_Signed.pdf) |
| 8 April 2026 - Board approved two whole-time director redesignations and appointed H B Kalaria & Associates as auditors from 10.04.2026. | [Outcome of Board Meeting 8 April 2026 - Board approved two whole-time director redesignations and appointed H B Kalaria & Associates as auditors from 10.04.2026.](https://nsearchives.nseindia.com/corporate/CEDAAR_08042026181642_NSE_Outcome_of_board_meeting.pdf) |
| 7 Jul - Published newspaper advertisement for proposed registered office shift from Karnataka to Punjab. | [Copy of Newspaper Publication 7 Jul - Published newspaper advertisement for proposed registered office shift from Karnataka to Punjab.](https://nsearchives.nseindia.com/corporate/CEDAAR_07072026190914_Intimation_to_NSE_signed.pdf) |
| 6 March 2026 - CEDAAR TEXTILE LIMITED has informed about Resignation of Independent director. | [Resignation of Independent director 6 March 2026 - CEDAAR TEXTILE LIMITED has informed about Resignation of Independent director.](https://nsearchives.nseindia.com/corporate/CEDAAR_ROID_80111_KMP_Doc.zip) |
| 6 Feb - CFO Phaninder Nath P S resigns effective Feb 06, 2026 due to personal health issues. | [Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) 6 Feb - CFO Phaninder Nath P S resigns effective Feb 06, 2026 due to personal health issues.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5fc785ea-374f-4cb1-bc2c-181d85ed6103.pdf) |
| 4 March 2026 - Clarification to NSE on Nov 21, 2025 financial results; unaudited H1 Sept 30, 2025 results; IPO proceeds utilized ₹54.45 crore. | [Reply to Clarification- Financial results 4 March 2026 - Clarification to NSE on Nov 21, 2025 financial results; unaudited H1 Sept 30, 2025 results; IPO proceeds utilized ₹54.45 crore.](https://nsearchives.nseindia.com/corporate/CEDAAR_25022026174621_CLarification_letter_with_annexures_25022026.pdf) |
| 4 June 2026 - Monitoring Agency report for the period ended on March 31, 2026 | [Monitoring Agency Report 4 June 2026 - Monitoring Agency report for the period ended on March 31, 2026](https://nsearchives.nseindia.com/corporate/CEDAAR_04062026153642_Monitoring_Agency_Report.zip) |
| 30 May 2026 - Audited FY26 results show Rs 84 crore inventory write-down, loan default, and auditor disclaimer opinion. | [Outcome of Board Meeting 30 May 2026 - Audited FY26 results show Rs 84 crore inventory write-down, loan default, and auditor disclaimer opinion.](https://nsearchives.nseindia.com/corporate/CEDAAR_30052026184940_Outcome_of_BM_on_30052026signed.pdf) |
| 30 March 2026 - Trading window closed from 01.04.2026 until 48 hours after audited results for period ended 31.03.2026. | [Trading Window 30 March 2026 - Trading window closed from 01.04.2026 until 48 hours after audited results for period ended 31.03.2026.](https://nsearchives.nseindia.com/corporate/CEDAAR_30032026165920_Trading_window_Closure_signed.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_29170_CEDAAR_2024_2025_A_4037147_24102025194423.pdf) |
| from nse | [Financial Year 2011 from nse](https://archives.nseindia.com/annual_reports/AR_VIVIMEDLAB_2010_2011_25102011045556.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/aa651044-9ab8-4f61-b862-65b6ac46ff36.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72158708-206c-4dd4-bcbe-7d272e62b093.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fceb4bc2-4e76-4188-a4f5-388c7b8c7642.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e6bf2a2d-73df-4a04-b8e9-d3be8d75d6ac.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0ccc72f2-3c86-481d-8359-a0f01961a3e4.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532660/68106532660.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/532660/5326600319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/532660/5326600318.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2018 | [Concall - Nov 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/11/66647ad4-f109-4f8c-ba5f-61c6acdca045.pdf) |
| Nov 2017 | [Concall - Nov 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/11/8308cdfb-8aa6-49fa-a5de-42f1da98abf2.pdf) |
| Mar 2019 | [Concall - Mar 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3fc8dc06-1077-4ee9-8707-4d59f40674df.pdf) |
| Jun 2018 | [Concall - Jun 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/6/f4cb9b4a-0887-4be8-95f0-a7ea14ae823d.pdf) |
| Feb 2018 | [Concall - Feb 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/2/3296e6da-cb6c-4e4d-9d6f-e2a2f201dee2.pdf) |
| Aug 2019 | [Concall - Aug 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/84f6ed7f-718f-4dfb-989c-cab91b2d90ad.pdf) |
| Aug 2018 | [Concall - Aug 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/8/ed39a138-077a-40ab-a511-079456bc1b31.pdf) |
| Aug 2015 | [Concall - Aug 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6A256C30_8085_4F08_BE38_3FE60A341C11_113659.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T21:38:43.994Z.